EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH

View source ↗

Summary

EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, giant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• RoActemra (tocilizumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection. MAH: Roche Registration GmbH. Decision date: 12/02/2026